The mechanism, efficacy, and tolerability profile of agomelatine

Bibliography

• Tardito D, Molteni R, Popoli M, Racagni G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol 2012;22(Suppl 3):S482-6
   PubMedGoogle Scholar
• Van RO, Weibel L, Olivares E, et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001;280(5):R1582-91
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306(3):954-64
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003;28(4):694-703
   PubMed Web of Science ®Google Scholar
• Hall P, Spear FG, Stirland D. Diurnal variation of subjective mood in depressive states. Psychiatr Q 1964;38:529-36
   PubMed Web of Science ®Google Scholar
• Malhi GS, Kuiper S. Chronobiology of mood disorders. Acta Psychiatr Scand Suppl 2013(444):2-15
   PubMedGoogle Scholar
• Emens J, Lewy A, Kinzie JM, et al. Circadian misalignment in major depressive disorder. Psychiatry Res 2009;168(3):259-61
   PubMed Web of Science ®Google Scholar
• Drennan MD, Klauber MR, Kripke DF, Goyette LM. The effects of depression and age on the Horne-Ostberg morningness-eveningness score. J Affect Disord 1991;23(2):93-8
   PubMed Web of Science ®Google Scholar
• Shirayama M, Shirayama Y, Iida H, et al. The psychological aspects of patients with delayed sleep phase syndrome (DSPS). Sleep Med 2003;4(5):427-33
   PubMed Web of Science ®Google Scholar
• Sack DA, Nurnberger J, Rosenthal NE, et al. Potentiation of antidepressant medications by phase advance of the sleep-wake cycle. Am J Psychiatry 1985;142(5):606-8
   PubMed Web of Science ®Google Scholar
• Modell S, Ising M, Holsboer F, Lauer CJ. The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol Psychiatry 2005;58(9):694-9
   PubMed Web of Science ®Google Scholar
• Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009;33(5):699-771
   PubMed Web of Science ®Google Scholar
• Kishi T, Kitajima T, Ikeda M, et al. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci 2009;259(5):293-7
   PubMed Web of Science ®Google Scholar
• Soria V, Martinez-Amoros E, Escaramis G, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010;35(6):1279-89
   PubMed Web of Science ®Google Scholar
• Lavebratt C, Sjoholm LK, Partonen T, et al. PER2 variantion is associated with depression vulnerability. Am J Med Genet B Neuropsychiatr Genet 2010;153B(2):570-81
   PubMed Web of Science ®Google Scholar
• Courtet P, Olie E. Circadian dimension and severity of depression. Eur Neuropsychopharmacol 2012;22(Suppl 3):S476-81
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379(9820):1045-55
   PubMed Web of Science ®Google Scholar
• Benedetti F, Radaelli D, Bernasconi A, et al. Clock genes beyond the clock: CLOCK genotype biases neural correlates of moral valence decision in depressed patients. Genes Brain Behav 2008;7(1):20-5
   PubMed Web of Science ®Google Scholar
• Audinot V, Mailliet F, Lahaye-Brasseur C, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003;367(6):553-61
   PubMed Web of Science ®Google Scholar
• Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010;25(3):117-31
   PubMed Web of Science ®Google Scholar
• Soumier A, Banasr M, Lortet S, et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009;34(11):2390-403
   PubMed Web of Science ®Google Scholar
• Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010;11(2):148-53
   PubMed Web of Science ®Google Scholar
• Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011;12(8):574-87
   PubMed Web of Science ®Google Scholar
• Tardito D, Milanese M, Bonifacino T, et al. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci 2010;11:68
   PubMed Web of Science ®Google Scholar
• Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 1998;13(1):39-51
   PubMed Web of Science ®Google Scholar
• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60(5):441-60
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17(5):239-47
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16(2):93-100
   PubMed Web of Science ®Google Scholar
• Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10(5):661-73
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(8):1128-37
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30(2):135-44
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71(5):616-26
   PubMed Web of Science ®Google Scholar
• Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68(11):1723-32
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28(3):329-33
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71(2):109-20
   PubMed Web of Science ®Google Scholar
• Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010;25(6):305-14
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011;26(5):252-62
   PubMed Web of Science ®Google Scholar
• Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 2013;10:1-16
   Google Scholar
• Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011;15:1-12
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71(10):1259-72
   PubMed Web of Science ®Google Scholar
• Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23(3):176-94
   PubMed Web of Science ®Google Scholar
• Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006;67(11):1754-9
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont) 2010;7(10):14-18
   Google Scholar
• Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-8
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65(3):328-36
   PubMed Web of Science ®Google Scholar
• Servier. Agomelatine: summary of product characteristics. Available from: http://www.valdoxan.com/index.php/valdoxan-package-leaflet-information-for-the-user/ [Retrieved 25 October 2013]
   Google Scholar
• Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007;103(1-3):77-82
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22(5):283-91
   PubMed Web of Science ®Google Scholar